BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37493210)

  • 1. Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.
    Singh N; Hocking AM; Buckner JH
    Immunol Rev; 2023 Sep; 318(1):81-88. PubMed ID: 37493210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
    Berner F; Flatz L
    Immunol Rev; 2023 Sep; 318(1):37-50. PubMed ID: 37548043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell tolerant fraction as a predictor of immune-related adverse events.
    Ostmeyer J; Park JY; von Itzstein MS; Hsiehchen D; Fattah F; Gwin M; Catalan R; Khan S; Raj P; Wakeland EK; Xie Y; Gerber DE
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37580069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
    Mathias K; Rouhani S; Olson D; Bass AR; Gajewski TF; Reid P
    Oncologist; 2023 May; 28(5):440-448. PubMed ID: 36595378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of B cells in immune-related adverse events following checkpoint blockade.
    Dhodapkar KM; Duffy A; Dhodapkar MV
    Immunol Rev; 2023 Sep; 318(1):89-95. PubMed ID: 37421187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
    Schulz TU; Zierold S; Sachse MM; Pesch G; Tomsitz D; Schilbach K; Kähler KC; French LE; Heinzerling L
    Eur J Cancer; 2022 Nov; 176():88-99. PubMed ID: 36198246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival.
    McGonagle D; Bragazzi NL; Amital H; Watad A
    Autoimmun Rev; 2020 Feb; 19(2):102456. PubMed ID: 31838166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity.
    Thanarajasingam U; Abdel-Wahab N
    Rheum Dis Clin North Am; 2020 Aug; 46(3):587-603. PubMed ID: 32631606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy.
    Lechner MG; Cheng MI; Patel AY; Hoang AT; Yakobian N; Astourian M; Pioso MS; Rodriguez ED; McCarthy EC; Hugo W; Angell TE; Drakaki A; Ribas A; Su MA
    J Immunol; 2022 Aug; 209(4):696-709. PubMed ID: 35817515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
    Khan S; Gerber DE
    Semin Cancer Biol; 2020 Aug; 64():93-101. PubMed ID: 31330185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon α.
    Dasgupta A; Tsay E; Federman N; Lechner MG; Su MA
    Pediatrics; 2022 Apr; 149(4):. PubMed ID: 35274131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
    Barth DA; Stanzer S; Spiegelberg J; Bauernhofer T; Absenger G; Posch F; Lipp R; Halm M; Szkandera J; Balic M; Gerger A; Smolle MA; Hutterer GC; Klec C; Jost PJ; Kargl J; Stradner M; Pichler M
    Cancer Med; 2022 Aug; 11(16):3074-3083. PubMed ID: 35297215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurologic manifestations of autoimmunity with immune checkpoint inhibitors.
    McCombe JA; Sechi E; Zekeridou A
    Handb Clin Neurol; 2024; 200():449-465. PubMed ID: 38494296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
    Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management.
    Williams SG; Mollaeian A; Katz JD; Gupta S
    Expert Rev Clin Immunol; 2020 Aug; 16(8):771-785. PubMed ID: 32772596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.